ONECUT2 is a novel target for treatment of castration-resistant prostate cancer

Expert Opin Ther Targets. 2020 Feb;24(2):89-90. doi: 10.1080/14728222.2020.1723080. Epub 2020 Feb 3.

Authors

Tejashree Joglekar^{1

2}, Jianqing Lin^{2

3}, Maho Shibata^{1

2}

Affiliations

¹ Department of Anatomy and Cell Biology, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
² The George Washington University Cancer Center, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
³ Division of Hematology/Oncology, Department of Medicine, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA.

No abstract available

Keywords: AR-independent prostate cancer; ONECUT2; castration-resistant prostate cancer; neuroendocrine prostate cancer; prostate cancer.

Publication types

Editorial
Research Support, N.I.H., Extramural

MeSH terms

Antineoplastic Agents / pharmacology*
Drug Resistance, Neoplasm
Homeodomain Proteins / metabolism*
Humans
Male
Molecular Targeted Therapy
Prostatic Neoplasms, Castration-Resistant / drug therapy*
Prostatic Neoplasms, Castration-Resistant / pathology
Receptors, Androgen / metabolism
Transcription Factors / metabolism*

Substances

Antineoplastic Agents
Homeodomain Proteins
ONECUT2 protein, human
Receptors, Androgen
Transcription Factors

Grants and funding

R00 CA194287/CA/NCI NIH HHS/United States